How has the COVID-19 pandemic affected eczema self-management and help seeking? A qualitative interview study with young people and parents/carers of children with eczema [0.03%]
COVID-19大流行如何影响了年轻人和患有湿疹的儿童的父母/护理人员对湿疹的自我管理和寻求帮助的方式？一项质性访谈研究
M Steele,L Howells,M Santer et al.
M Steele et al.
Background: Eczema can have a considerable impact on quality of life. Treatments can improve this, but management is complex. Barriers to eczema self-management may be impacted upon by environmental context, such as the C...
S Yuen
S Yuen
The article discusses the impact of COVID-19 on the future of dermatology services. It will explore the changes dermatology services may need to follow to minimise disease transmission. This will include an integration of teledermatology in...
A systematic review of dermatologic manifestations among adult patients with COVID-19 diagnosis [0.03%]
新型冠状病毒成人患者皮肤病症状的系统性回顾研究论文
L N Schwartzberg,S Advani,D C Clancy et al.
L N Schwartzberg et al.
Background: Infection with COVID-19 is characterized by respiratory, gastrointestinal and neurologic symptoms. However, limited evidence exists of the involvement of the integumentary system among COVID-19 patients and ev...
Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid-19 pandemic: A UK dermatology tertiary centre experience [0.03%]
英国一家皮肤病三级诊疗中心新冠肺炎流行期间生物制剂治疗慢性斑块状银屑病和汗腺炎患者的疗效
S Khan,D Karponis,G Wali
S Khan
Retrospective review data from 183 patients with psoriasis and/or hidradenitis suppurativa from a UK tertiary dermatology centre, suggests biologic therapy does not confer a significant increased risk of contracting severe Covid-19 in this ...
Itraconazole-associated purpuric drug eruption: a rare adverse effect of a commonly prescribed drug [0.03%]
伊曲康唑引起的紫癜型药疹：一种常用药物的罕见不良反应
Purpuric drug eruption (PDE) is a rare drug reaction characterized by purpuric macules, papules and confluent plaques predominantly on the lower extremities. The drugs reported to induce PDE are epidermal growth factor receptor inhibitors, ...